BACKGROUND: In sepsis, excessive generation of reactive oxygen species plays key roles in the pathogenesis of acute lung injury. The serum antioxidants such as catalase and MnSOD are elevated in sepsis and considered as predictors of acute respiratory distress syndrome(ARDS) and prognostic factors of sepsis. Peroxiredoxin(Prx) has recently been known as an unique and major intracellular antioxidant. In this study, we evaluated the expression of Prx I and Prx II in mouse monocyte-macrophage cells(RAW267.7) after treatment of oxidative stress and endotoxin and measured the amount of Prx I, Prx II and thioredoxin(Trx) in peritoneal and bronchoalveolar lavage fluid of septic animal model. METHODS: Using immunoblot analysis with specific antibodies against Prx I, Prx II and Trx, we evaluated the distribution of Prx I and Prx II in human neutrophil, alveolar macrophage and red blood cell. We evaluated the expression of Prx I and Prx II in mouse monocyte-macrophage cells after treatment of 5 micro M menadione and 1 micro gram/ml lipopolysaccharide(LPS) and measured the amount of Prx I, Prx II and Trx in peritoneal lavage fluid of intraperitoneal septic animals(septic animal model induced with intraperitoneal 6 micro gram/kg LPS injection) and those in bronchoalveolar lavage fluid of intraperitoneal septic animals and intravenous septic animals(septic animal model induced with intravenous 5 micro gram/kg LPS injection) and compared with the severity of lung inflammation. RESULTS: The distribution of Prx I and Prx II were so different among human neutrophil, alveolar macrophage and red blood cell. The expression of Prx I in mouse monocyte-macrophage cells was increased after treatment of 5 micro M menadione and 1 micro gram/ml lipopolysaccharide but that of Prx II was not increased. The amount of Prx I, Prx II and Trx are increased in peritoneal lavage fluid of intraperitoneal septic animals but were not increased in bronchoalveolar lavage fluid of intraperitoneal and intravenous septic animals regardless of the severity of lung inflammation. CONCLUSION: As intracellular antioxidant, the expression of Prx I is increased in mouse monocyte-macrophage cells after treatment of oxidative stress and endotoxin. The amount of Prx I, Prx II and Trx are increased in local inflammatory site but not increased in injured lung of septic animal model.
Acute Lung Injury ; Animals* ; Antibodies ; Antioxidants ; Bronchoalveolar Lavage ; Bronchoalveolar Lavage Fluid ; Catalase ; Erythrocytes ; Humans ; Lung ; Macrophages, Alveolar ; Mice ; Models, Animal* ; Neutrophils ; Oxidative Stress ; Peritoneal Lavage ; Peroxiredoxins* ; Pneumonia ; Reactive Oxygen Species ; Sepsis ; Thioredoxins* ; Vitamin K 3

PURPOSE: Apoptosis is known to be induced either by direct oxidative damage from oxygen free radicals or hydrogen peroxide, or from their generation in cells by injurious agents. Peroxiredoxin plays an important role in eliminating peroxides generated during metabolism. The aim of this study is to elucidate the role of Prx (peroxiredoxin) enzymes during the cellular response to oxidative stress. METHODS: The presence of Prx isoforms was demonstrated by immunoblot analysis using Prx isoforms-specific antibodies, and RT-PCR using Prx isozyme coding sequences. Annexin V-FITO apoptosis detection method was used to measure the cell death following exposure to H2O2. RESULTS: Treatment of MCF7 cell lines with H2O2 resulted in the dose-dependent expression of Prx I and II. Observed decreases in the mRNA expressions of Prx I and II, analyzed by RT-PCR, correlated well with the results of immunoblot analysis. The treatment of normal breast cell line, MCF10A, with H2O2 resulted in rapid cell death, while the breast cancer cell line, MCF7, was resistant. In addition, we confirmed that Prx I and II transfected MCF10A cells were more prone to cell death than MCF10A transfected with vector alone, after H2O2 treatment. CONCLUSION: These findings suggest that Prx I and II have an important function as inhibitors of cell death during the cellular response to oxidative stress.
Antibodies ; Apoptosis* ; Breast ; Breast Neoplasms ; Cell Death ; Cell Line ; Clinical Coding ; Free Radicals ; Hydrogen Peroxide ; MCF-7 Cells* ; Metabolism ; Oxidative Stress ; Oxygen ; Peroxides ; Peroxiredoxins ; Protein Isoforms ; RNA, Messenger

OBJECTIVES: Thioredoxin peroxidase(TPx), which does not exhibit similar activity and amino acid sequence homology to conventional antioxidant enzymes has been purified from S cerevisiae and bovine brain. Natural killer enhancing factor-A(NKEF-A)/ proliferation associated gene(PAG), natural killer enhancing factor-B(NKEF-B)/TPx and MER5 which has sequence homology to yeast TPx has been recently characterized biochemically, Prosperi has reported that the level of PAG in HL-60 cells was increased after serum stimulation and decreased after differentiation induced by DMSO treatment. It is well known that thioredoxin, the electron donor to thioredoxin peroxidase, also implicated in cell proliferation via protein kinase C pathway. Disturbed balance of reactive oxygen species and antioxidant in tumor tissue could enhance the cancer promotion This study was designed to investigate the distribution of NKEF-A/FAG, NKEF-B/TPx and MER5 in various tissues, and the expression of NKEF-A/PAG, NKEF-B/TPx and MER5 in human cancers. METHODS: We used antibodies against the purified recombinant protein of NKEF-A/PAG and NKEF-B/TPx and C-terminus amino acids(SP-TASKEYFEKVHO) of MER5, We separated cytosole and mitochondria from rat liver and prepared crude extract from these. We prepared crude extract of various tissues from rat and cancer tissue from lung, stomach and breast and paired normal tissue. Immunoblot analysis of these crude extracts was performed. RESULTS: 1) NKEF-A/PAG and NKEF-B/TPx existed in cytosolic fraction as Cu, Zn-SOD and MER5 mainly exist mainly in mitochondrial fraction as Mn-SOD. Although the level of NKEF-AIPAG, NKEF-B/TPx and MER5 was different, all tissues exhibited NKEF-A/PAG, NKEF-B/TPx and MER5 immunoreactive bands. The adrenal gland had relatively strong band of MEK. 2) The expression of NKEF-A/PAG in HL-60 cell was increased after serum stimulation and decreased after cell differentiation induced by DMSO treatment. 3) The expression of NKEF-A/PAG was increased in lung and breast cancer tissues compaired to paired normal tissues but was not changed in stomach cancer tissues and the expression of NKEF-B/TPx and MER5 was not changed in lung, stomach and breast cancer tissues compaired to paired normal tissues. 4) The level of NKEF-A/PAG, NKEF-B/TPx and MER5 was not different among various lung cancer cell lines. CONCLUSION: The NKEF-A/PAG, NKRF-B/TPx and MER5 are present in the cytosol and mitochondria of various tissues. The NKEF-A/PAG, in particular, is associated with cell proliferation and differentiation and overexpressed in lung and breast cancer.
Adrenal Glands ; Animals ; Antibodies ; Brain ; Breast ; Breast Neoplasms ; Cell Differentiation ; Cell Line ; Cell Proliferation ; Complex Mixtures ; Cytosol ; Dimethyl Sulfoxide ; HL-60 Cells ; Humans* ; Liver ; Lung ; Lung Neoplasms ; Mitochondria ; Peroxidases* ; Peroxiredoxins ; Protein Kinase C ; Rats ; Reactive Oxygen Species ; Saccharomyces cerevisiae ; Sequence Homology ; Sequence Homology, Amino Acid ; Stomach ; Stomach Neoplasms ; Superoxide Dismutase ; Thioredoxins* ; Tissue Donors ; Yeasts

BACKGROUND: There has been no practical guidelines for the management of patients with central nervous system (CNS) tumors in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, started to prepare guidelines for CNS tumors from February 2018. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified through searches of PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL using specific and sensitive keywords as well as combinations of keywords. RESULTS: First, the maximal safe resection if feasible is recommended. After the diagnosis of a glioblastoma with neurosurgical intervention, patients aged ≤70 years with good performance should be treated by concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide chemotherapy (Stupp's protocol) or standard brain radiotherapy alone. However, those with poor performance should be treated by hypofractionated brain radiotherapy (preferred)±concurrent or adjuvant temozolomide, temozolomide alone (Level III), or supportive treatment. Alternatively, patients aged >70 years with good performance should be treated by hypofractionated brain radiotherapy+concurrent and adjuvant temozolomide or Stupp's protocol or hypofractionated brain radiotherapy alone, while those with poor performance should be treated by hypofractionated brain radiotherapy alone or temozolomide chemotherapy if the patient has methylated MGMT gene promoter (Level III), or supportive treatment. CONCLUSION: The KSNO's guideline recommends that glioblastomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to the individual comprehensive condition of the patient.
Brain ; Central Nervous System ; Chemoradiotherapy ; Diagnosis ; Drug Therapy ; Glioblastoma ; Humans ; Korea ; Radiotherapy

BACKGROUND: There was no practical guideline for the management of patients with central nervous system tumor in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, has developed the guideline for glioblastoma. Subsequently, the KSNO guideline for World Health Organization (WHO) grade II cerebral glioma in adults is established. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified by searching PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords regarding diffuse astrocytoma and oligodendroglioma of brain in adults. RESULTS: Whenever radiological feature suggests lower grade glioma, the maximal safe resection if feasible is recommended globally. After molecular and histological examinations, patients with diffuse astrocytoma, isocitrate dehydrogenase (IDH)-wildtype without molecular feature of glioblastoma should be primarily treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy (Level III) while those with molecular feature of glioblastoma should be treated following the protocol for glioblastomas. In terms of patients with diffuse astrocytoma, IDH-mutant and oligodendroglioma (IDH-mutant and 1p19q codeletion), standard brain radiotherapy and adjuvant PCV (procarbazine+lomustine+vincristine) combination chemotherapy should be considered primarily for the high-risk group while observation with regular follow up should be considered for the low-risk group. CONCLUSION: The KSNO's guideline recommends that WHO grade II gliomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to molecular and histological features of tumors and clinical characteristics of patients.
Adult ; Astrocytoma ; Brain ; Central Nervous System ; Drug Therapy ; Drug Therapy, Combination ; Follow-Up Studies ; Glioblastoma ; Glioma ; Humans ; Isocitrate Dehydrogenase ; Korea ; Oligodendroglioma ; Radiotherapy ; World Health Organization

BACKGROUND: There was no practical guideline for the management of patients with central nervous system tumor in Korea in the past. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, developed the guideline for glioblastoma successfully and published it in Brain Tumor Research and Treatment, the official journal of KSNO, in April 2019. Recently, the KSNO guideline for World Health Organization (WHO) grade III cerebral glioma in adults has been established. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified by searches in PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords. Scope of the disease was confined to cerebral anaplastic astrocytoma and oligodendroglioma in adults. RESULTS: Whenever radiological feature suggests high grade glioma, maximal safe resection if feasible is globally recommended. After molecular and histological examinations, patients with anaplastic astrocytoma, isocitrate dehydrogenase (IDH)-mutant should be primary treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy whereas those with anaplastic astrocytoma, NOS, and anaplastic astrocytoma, IDH-wildtype should be treated following the protocol for glioblastomas. In terms of anaplastic oligodendroglioma, IDH-mutant and 1p19q-codeletion, and anaplastic oligodendroglioma, NOS should be primary treated by standard brain radiotherapy and neoadjuvant or adjuvant PCV (procarbazine, lomustine, and vincristine) combination chemotherapy. CONCLUSION: The KSNO's guideline recommends that WHO grade III cerebral glioma of adults should be treated by maximal safe resection if feasible, followed by radiotherapy and/or chemotherapy according to molecular and histological features of tumors.
Adult ; Astrocytoma ; Brain ; Brain Neoplasms ; Central Nervous System ; Drug Therapy ; Drug Therapy, Combination ; Glioblastoma ; Glioma ; Humans ; Isocitrate Dehydrogenase ; Korea ; Lomustine ; Oligodendroglioma ; Radiotherapy ; World Health Organization